• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

线粒体丙酮酸载体:糖尿病肾病的潜在靶点。

Mitochondrial pyruvate carrier: a potential target for diabetic nephropathy.

机构信息

Department of Nephrology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 300 Guangzhou Road, Nanjing, 210029, Jiangsu Province, P. R. of China.

出版信息

BMC Nephrol. 2020 Jul 14;21(1):274. doi: 10.1186/s12882-020-01931-5.

DOI:10.1186/s12882-020-01931-5
PMID:32664896
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7362444/
Abstract

BACKGROUND

Mitochondrial dysfunction contributes to the pathogenesis of diabetic nephropathy (DN). Mitochondrial pyruvate carrier 1 (MPC1) and mitochondrial pyruvate carrier 2 (MPC2) play a bottleneck role in the transport of pyruvate into mitochondrial across the mitochondrial inner membrane. A previous study showed that increasing mitochondrial pyruvate carrier content might ameliorate diabetic kidney disease in db/db mice. However, the expression status of MPC1 and MPC2 in patients with DN is unclear.

METHODS

Patients with primary glomerulonephropathy (PGN, n = 30), PGN with diabetes mellitus (PGN-DM, n = 30) and diabetic nephropathy (DN, n = 30) were included. MPC1 and MPC2 protein levels were examined by immunohistochemistry. The expression of MPC in different groups was evaluated by the Kruskal-Wallis test. Spearman's rank correlation was performed for correlation analysis between MPC levels and clinical factors.

RESULTS

Both MPC1 and MPC2 were localized in renal tubules. Levels of MPC1 and MPC2 were lower in DN patients than in PGN patients and in PGN patients with DM, whereas there were no differences in MPC1 and MPC2 levels among DN stage II to stage IV. Moreover, both MPC1 and MPC2 levels were significantly correlated with serum creatinine, BUN and eGFR in patients with DN, whereas no analogous trend was observed in nondiabetic kidney disease.

CONCLUSIONS

Our study indicated that MPC localized in renal tubules, which were significantly decreased in DN. MPC was associated with clinical features, especially those representing renal functions.

摘要

背景

线粒体功能障碍导致糖尿病肾病(DN)的发病机制。线粒体丙酮酸载体 1(MPC1)和线粒体丙酮酸载体 2(MPC2)在丙酮酸穿过线粒体内膜进入线粒体的运输中起着瓶颈作用。先前的研究表明,增加线粒体丙酮酸载体的含量可能改善 db/db 小鼠的糖尿病肾病。然而,DN 患者 MPC1 和 MPC2 的表达状态尚不清楚。

方法

纳入原发性肾小球肾炎(PGN,n=30)、合并糖尿病的 PGN(PGN-DM,n=30)和糖尿病肾病(DN,n=30)患者。通过免疫组织化学法检测 MPC1 和 MPC2 蛋白水平。采用 Kruskal-Wallis 检验评估不同组中 MPC 的表达。采用 Spearman 秩相关分析 MPC 水平与临床因素之间的相关性。

结果

MPC1 和 MPC2 均定位于肾小管。DN 患者的 MPC1 和 MPC2 水平低于 PGN 患者和 PGN-DM 患者,而在 DN Ⅱ期至Ⅳ期患者中,MPC1 和 MPC2 水平无差异。此外,MPC1 和 MPC2 水平与 DN 患者的血清肌酐、BUN 和 eGFR 均呈显著相关,而在非糖尿病肾病患者中则无类似趋势。

结论

本研究表明,定位于肾小管的 MPC 在 DN 中明显减少。MPC 与临床特征相关,特别是与肾功能相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e198/7362444/d682a75f58d5/12882_2020_1931_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e198/7362444/3d9bdd5fc922/12882_2020_1931_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e198/7362444/01f8ddb1adc2/12882_2020_1931_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e198/7362444/6c0975aa65a9/12882_2020_1931_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e198/7362444/d682a75f58d5/12882_2020_1931_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e198/7362444/3d9bdd5fc922/12882_2020_1931_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e198/7362444/01f8ddb1adc2/12882_2020_1931_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e198/7362444/6c0975aa65a9/12882_2020_1931_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e198/7362444/d682a75f58d5/12882_2020_1931_Fig4_HTML.jpg

相似文献

1
Mitochondrial pyruvate carrier: a potential target for diabetic nephropathy.线粒体丙酮酸载体:糖尿病肾病的潜在靶点。
BMC Nephrol. 2020 Jul 14;21(1):274. doi: 10.1186/s12882-020-01931-5.
2
Association of Mitochondrial Pyruvate Carrier with the Clinical and Histological Features in Lupus Nephritis.线粒体丙酮酸载体与狼疮性肾炎临床及组织学特征的关联
Int J Nephrol Renovasc Dis. 2024 Jan 19;17:29-38. doi: 10.2147/IJNRD.S443519. eCollection 2024.
3
MPC1-like Is a Placental Mammal-specific Mitochondrial Pyruvate Carrier Subunit Expressed in Postmeiotic Male Germ Cells.类MPC1是一种胎盘哺乳动物特有的线粒体丙酮酸载体亚基,在减数分裂后的雄性生殖细胞中表达。
J Biol Chem. 2016 Aug 5;291(32):16448-61. doi: 10.1074/jbc.M116.733840. Epub 2016 Jun 17.
4
Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.线粒体丙酮酸载体在异柠檬酸脱氢酶突变型脑胶质瘤中的预后作用。
J Neurosurg. 2019 Jan 1;130(1):56-66. doi: 10.3171/2017.9.JNS172036.
5
MPC1 and MPC2 expressions are associated with favorable clinical outcomes in prostate cancer.MPC1和MPC2的表达与前列腺癌良好的临床预后相关。
BMC Cancer. 2016 Nov 16;16(1):894. doi: 10.1186/s12885-016-2941-6.
6
Structural Insights into the Human Mitochondrial Pyruvate Carrier Complexes.结构洞察人类线粒体丙酮酸载体复合物。
J Chem Inf Model. 2021 Nov 22;61(11):5614-5625. doi: 10.1021/acs.jcim.1c00879. Epub 2021 Oct 19.
7
Two human patient mitochondrial pyruvate carrier mutations reveal distinct molecular mechanisms of dysfunction.两种人类患者的线粒体丙酮酸载体突变揭示了功能障碍的不同分子机制。
JCI Insight. 2019 May 30;5(13):126132. doi: 10.1172/jci.insight.126132.
8
Identification and characterization of novel MPC1 gene variants causing mitochondrial pyruvate carrier deficiency.导致线粒体丙酮酸载体缺乏的新型MPC1基因变异体的鉴定与特征分析。
J Inherit Metab Dis. 2022 Mar;45(2):264-277. doi: 10.1002/jimd.12462. Epub 2022 Jan 8.
9
NMR and Patch-Clamp Characterization of Yeast Mitochondrial Pyruvate Carrier Complexes.NMR 和膜片钳技术对酵母线粒体丙酮酸载体复合物的表征。
Biomolecules. 2023 Apr 22;13(5):719. doi: 10.3390/biom13050719.
10
Mitochondrial pyruvate carrier 1 functions as a tumor suppressor and predicts the prognosis of human renal cell carcinoma.线粒体丙酮酸载体 1 作为一种肿瘤抑制因子,可预测人肾细胞癌的预后。
Lab Invest. 2019 Feb;99(2):191-199. doi: 10.1038/s41374-018-0138-0. Epub 2018 Oct 5.

引用本文的文献

1
Advances in the Development of Mitochondrial Pyruvate Carrier Inhibitors for Therapeutic Applications.用于治疗应用的线粒体丙酮酸载体抑制剂的开发进展
Biomolecules. 2025 Feb 3;15(2):223. doi: 10.3390/biom15020223.
2
Mitochondrial pyruvate carrier 2 mitigates acute kidney injury via sustaining mitochondrial metabolism.线粒体丙酮酸载体 2 通过维持线粒体代谢减轻急性肾损伤。
Int J Biol Sci. 2024 Aug 19;20(11):4551-4565. doi: 10.7150/ijbs.98627. eCollection 2024.
3
Association of Mitochondrial Pyruvate Carrier with the Clinical and Histological Features in Lupus Nephritis.

本文引用的文献

1
Regulation of Tumor Initiation by the Mitochondrial Pyruvate Carrier.线粒体丙酮酸载体对肿瘤起始的调控。
Cell Metab. 2020 Feb 4;31(2):284-300.e7. doi: 10.1016/j.cmet.2019.11.002. Epub 2019 Dec 5.
2
Diabetic kidney diseases revisited: A new perspective for a new era.重新审视糖尿病肾病:新时代的新视角。
Mol Metab. 2019 Dec;30:250-263. doi: 10.1016/j.molmet.2019.10.005. Epub 2019 Oct 17.
3
Mitochondrial pyruvate carrier 2 mediates mitochondrial dysfunction and apoptosis in high glucose-treated podocytes.线粒体丙酮酸载体 2 在高糖处理的足细胞中介导线粒体功能障碍和细胞凋亡。
线粒体丙酮酸载体与狼疮性肾炎临床及组织学特征的关联
Int J Nephrol Renovasc Dis. 2024 Jan 19;17:29-38. doi: 10.2147/IJNRD.S443519. eCollection 2024.
4
MPC2 variants disrupt mitochondrial pyruvate metabolism and cause an early-onset mitochondriopathy.MPC2 变异破坏线粒体丙酮酸代谢,导致早发性线粒体病。
Brain. 2023 Mar 1;146(3):858-864. doi: 10.1093/brain/awac444.
5
Heart failure-emerging roles for the mitochondrial pyruvate carrier.心力衰竭-线粒体丙酮酸载体的新作用。
Cell Death Differ. 2021 Apr;28(4):1149-1158. doi: 10.1038/s41418-020-00729-0. Epub 2021 Jan 20.
6
Mitochondrial Pyruvate Carrier Function in Health and Disease across the Lifespan.线粒体丙酮酸载体在整个生命周期中的健康和疾病中的功能。
Biomolecules. 2020 Aug 8;10(8):1162. doi: 10.3390/biom10081162.
Life Sci. 2019 Nov 15;237:116941. doi: 10.1016/j.lfs.2019.116941. Epub 2019 Oct 10.
4
Targeting the Mitochondrial Pyruvate Carrier for Neuroprotection.靶向线粒体丙酮酸载体以实现神经保护
Brain Sci. 2019 Sep 18;9(9):238. doi: 10.3390/brainsci9090238.
5
Association of urinary acidification function with the progression of diabetic kidney disease in patients with type 2 diabetes.2 型糖尿病患者尿液酸化功能与糖尿病肾病进展的关系。
J Diabetes Complications. 2019 Nov;33(11):107419. doi: 10.1016/j.jdiacomp.2019.107419. Epub 2019 Aug 19.
6
Inhibition of ERRα Prevents Mitochondrial Pyruvate Uptake Exposing NADPH-Generating Pathways as Targetable Vulnerabilities in Breast Cancer.抑制 ERRα 可防止线粒体丙酮酸摄取,从而暴露出乳腺癌中可靶向利用的 NADPH 生成途径的脆弱性。
Cell Rep. 2019 Jun 18;27(12):3587-3601.e4. doi: 10.1016/j.celrep.2019.05.066.
7
The yeast mitochondrial pyruvate carrier is a hetero-dimer in its functional state.酵母线粒体丙酮酸载体在其功能状态下是一种异二聚体。
EMBO J. 2019 May 15;38(10). doi: 10.15252/embj.2018100785. Epub 2019 Apr 12.
8
Artemether ameliorates type 2 diabetic kidney disease by increasing mitochondrial pyruvate carrier content in db/db mice.蒿甲醚通过增加db/db小鼠线粒体丙酮酸载体含量改善2型糖尿病肾病。
Am J Transl Res. 2019 Mar 15;11(3):1389-1402. eCollection 2019.
9
The Mitochondria-Targeted Metabolic Tubular Injury in Diabetic Kidney Disease.糖尿病肾病中靶向线粒体的代谢性肾小管损伤
Cell Physiol Biochem. 2019;52(2):156-171. doi: 10.33594/000000011. Epub 2019 Feb 28.
10
SIRT3 deficiency leads to induction of abnormal glycolysis in diabetic kidney with fibrosis.SIRT3 缺乏导致糖尿病肾病伴纤维化中异常糖酵解的诱导。
Cell Death Dis. 2018 Sep 24;9(10):997. doi: 10.1038/s41419-018-1057-0.